Enforcement news, scam patterns, China supply-chain reporting, and quality-control guidance for the research peptide grey market.
Since November 2025, the FDA has sent over 50 warning letters to online peptide sellers in three coordinated waves. Here’s what the agency is actually targeting, using real letters as case studies.
BPC-157 just cleared a real hurdle — a favorable PCAC committee vote toward FDA’s 503A Bulk Drugs List — but it’s still not formally authorized for compounding. Here’s the full regulatory timeline and what’s still ahead.
The FDA’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list just finished its comment period. Here’s what changes, what doesn’t, and why the shortage-era compounding market is ending.
Fifty-four thousand customers. Eighty countries. Five million dollars in proceeds. And a product that, when federal investigators finally tested it,
Somewhere between December 2024 and March 2025, officers at U.S. Customs and Border Protection’s Cincinnati port of entry started noticing
In the span of about nine months, the research peptide market lost its largest vendor, watched federal agents physically raid
